Weiss Multi-Strategy Advisers’s Pacific Biosciences PACB Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-89,396	Closed	-$877K	–	336
2023 Q4	$877K	Buy	89,396 +18,396	+26%	+$150K	0.02%	446
2023 Q3	$593K	Buy	71,000 +14,105	+25%	+$161K	0.01%	470
2023 Q2	$757K	Sell	56,895 -6,004	-10%	-$73K	0.02%	559
2023 Q1	$728K	Buy	62,899 +12,827	+26%	+$128K	0.02%	528
2022 Q4	$410K	Buy	50,072 +10,271	+26%	+$88.5K	0.01%	524
2022 Q3	$231K	Sell	39,801 -1,285	-3%	-$7.37K	0.01%	600
2022 Q2	$182K	Buy	41,086 +11,271	+38%	+$68.5K	0.01%	621
2022 Q1	$271K	Buy	29,815 +3,930	+15%	+$45.2K	0.01%	610
2021 Q4	$530K	Sell	25,885 -115	-0.4%	-$2.77K	0.01%	546
2021 Q3	$664K	Buy	26,000 +638	+3%	+$18.9K	0.01%	528
2021 Q2	$887K	Sell	25,362 -4,696	-16%	-$137K	0.02%	503
2021 Q1	$1M	Sell	30,058 -54,942	-65%	-$1.92M	0.02%	480
2020 Q4	$2.21M	Sell	85,000 -85,000	-50%	-$1.44M	0.04%	405
2020 Q3	$1.68M	Sell	170,000 -53,640	-24%	-$309K	0.04%	372
2020 Q2	$772K	Sell	223,640 -4,034,894	-95%	-$13.7M	0.02%	437
2020 Q1	$13M	Buy	4,258,534 +4,151,834	+3,891%	+$17M	0.51%	56
2019 Q4	$548K	Buy	106,700 +16,700	+19%	+$84.9K	0.01%	532
2019 Q3	$464K	Buy	+90,000	New	+$503K	0.01%	497
2019 Q1	–	Sell	-49,543	Closed	-$367K	–	587
2018 Q4	$367K	Hold	49,543	–	–	0.02%	373
2018 Q3	$268K	Buy	49,543 +217	+0.4%	+$931	0.01%	483
2018 Q2	$175K	Buy	49,326 +4,326	+10%	+$12K	﹤0.01%	523
2018 Q1	$92K	Buy	45,000 +5,000	+13%	+$13K	﹤0.01%	511
2017 Q4	$106K	Sell	40,000 -66,500	-62%	-$233K	﹤0.01%	536
2017 Q3	$559K	Hold	106,500	–	–	0.02%	419
2017 Q2	$379K	Sell	106,500 -500	-0.5%	-$2.02K	0.02%	469
2017 Q1	$553K	Hold	107,000	–	–	0.02%	442
2016 Q4	$407K	Hold	107,000	–	–	0.02%	345
2016 Q3	$959K	Sell	107,000 -5,995	-5%	-$50.1K	0.06%	295
2016 Q2	$795K	Sell	112,995 -34,005	-23%	-$311K	0.06%	284
2016 Q1	$1.25M	Buy	147,000 +15,000	+11%	+$148K	0.05%	318
2015 Q4	$1.73M	Hold	132,000	–	–	0.12%	185
2015 Q3	$483K	Buy	132,000 +22,000	+20%	+$108K	0.02%	321
2015 Q2	$634K	Hold	110,000	–	–	0.03%	359
2015 Q1	$642K	Buy	110,000 +2,700	+3%	+$18.6K	0.03%	349
2014 Q4	$841K	Hold	107,300	–	–	0.03%	301
2014 Q3	$527K	Buy	107,300 +7,300	+7%	+$38.2K	0.01%	434
2014 Q2	$618K	Hold	100,000	–	–	0.01%	486
2014 Q1	$535K	Sell	100,000 -20,000	-17%	-$126K	0.01%	632
2013 Q4	$628K	Sell	120,000 -30,000	-20%	-$138K	0.01%	555
2013 Q3	$828K	Sell	150,000 -20,000	-12%	-$69.4K	0.02%	444
2013 Q2	$430K	Buy	+170,000	New	+$423K	0.01%	502

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Weiss Multi-Strategy Advisers's PACB Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 89,396 shares — an estimated $877K sold.

Weiss Multi-Strategy Advisers first reported a position in PACB in Q2 2013 and held it in 41 quarters. The position peaked at $13M in Q1 2020. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 89,396 Pacific Biosciences shares in Q1 2024, an estimated $877K.
Weiss Multi-Strategy Advisers first reported a position in Pacific Biosciences in Q2 2013 and held it in 41 quarters.
Weiss Multi-Strategy Advisers's Pacific Biosciences position peaked at $13M in Q1 2020.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.